Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis

Tuberculosis, the infection on the verge of eradication once, is now a great threat to mankind. Emergence of MDR and XDR-TB synergised with HIV and other immune-compressive diseases have increased the life threatening capacities of the disease. A small molecule has been identified here, which showed potent anti-tubercular activity. The identified hit compound has also been proved active against nearly 25 clinical isolates comparable with isoniazid.

A substituted oxadizole has been identified and then modified to yield 6e, a potent anti-tubercular agent. The anti-XDR & MDR-TB activity is discussed using 25 different isolates.Figure optionsDownload as PowerPoint slideHighlights
► Identification of novel tractable molecule by HTS is discussed.
► Analoging of newer chemotype, which has proved potent, is conferred.
► A report discussing antimycobacterial activity of hit compound with 25 clinical isolates.
► “Hit” arrived is easy, inexpensive and fast to synthesise.